United Kingdom (UK)
Recombinant monoclonal antibody to Glioma surface antigen. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the human B cell clone BT32/A6.
Alternative Name(s) of Target: SK-MG-1; Glioma cells
Immunogen: The original antibody was generated by fusing peripheral B lymphocytes (PBL) obtained from four patients with astrocytic tumors with human myeloma-like cell line TM-H2-SP2 to create hybridomas.
Specificity: This antibody (BT32/A6) recognizes a surface and cytoplasmic antigen present on a variety of human tumor cell lines including gliomas, melanomas, neuroblastomas, and a few sarcomas.
Application Notes: The binding specificity of the IgM version of this antibody for human glioma cell lines was tested using ELISA (PMID: 1545260). Further characterization of binding of the IgM version of this antibody to SK-MG-1 and other cultured human cell lines was done using flow cytometry (US5639863; PMID: 7861227). This antibody was also used for the immunoperoxidase staining of human tumor cells (US5639863). Point mutation were introduced to increase the solubility and thermal refolding efficiency the antibody (PMID: 16971398). This antibody was also used to identify the non-human cell lines, normal human tissues, tumors of central neuroepithelial origin which express the antigen it binds (PMID: 9266445).
Antibody first published in:
Dan et al. Human antiglioma monoclonal antibodies from patients with astrocytic tumors. J Neurosurg. 1992 Apr;76(4):660-9. PMID:1545260
Note on publication:
Describes the generation of antibodies against glioma cell lines from the peripheral blood lymphocytes of four patients with astrocytic tumors.